Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- MONDO_0005689 label "Cannabis dependence" assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Psychosis is broadly defined as a disengagement from reality. It describes syndromes that impair both thought content and thought process. Psychosis negatively impacts an individual's quality of life, in addition to the families caring for them. Psychosis with different types of hallucinations and delusions occurs in the context of delirium. Neuropsychiatric symptoms (NPS) are almost universal in the course of common neurodegenerative disorders (NDD) like Alzheimer's disease (AD) or Parkinson's disease (PD). In this paper, the authors took an effort to characterize AD and PD psychosis with a special focus on the most diagnostically reliable features. Quetiapine (see supplement) is also commonly used in (off-label) for NPS in AD." assertion.
- context label "Adults" assertion.
- HP_0000709 label "Psychosis" assertion.
- HP_0000709 label "Psychosis" assertion.
- HP_0000709 label "Psychosis" assertion.
- HP_0000709 label "Psychosis" assertion.
- association label "A 30-year-old insomniac, an off-label user of quetiapine, presented with blurring of central vision, eventually diagnosed as central serous chorioretinopathy." assertion.
- cohort label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- association label "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “history of migraines and depression, both well controlled on bupropion and amitriptyline”" assertion.
- association label "Clinician's annotation: “foot pain—chronic, not neuropathy apparently, will give trial of nortrip in case”" assertion.
- context label "Adults" assertion.
- HP_0025238 label "foot pain" assertion.
- association label "Clinician's annotation: “Has been taking increased dose of nortriptyline since last visit and notes much less pain radiating to leg”" assertion.
- context label "Adults" assertion.
- HP_0012531 label "pain" assertion.
- association label "Clinician's annotation: “Pt was told to continue Lexapro. RX options for her constipation were reviewed”" assertion.
- context label "Adults" assertion.
- MONDO_0002203 label "constipation disorder" assertion.
- association label "Cyclobenzaprine is frequently used off-label in fibromyalgia and is associated with improved pain, sleep, and fatigue in several studies." assertion.
- context label "adults" assertion.
- association label "Guidelines recommend the use of neuromodulators in patients with functional dyspepsia not responding to proton pump inhibitors (PPIs) and prokinetics; however, there is a lack of data from randomised controlled trials supporting their use." assertion.
- context label "adults" assertion.
- MONDO_0002268 label "Dyspepsia" assertion.
- association label "Tension-type headache (TTH) is the most common primary headache disorder, with a worldwide lifetime prevalence of 46% to 78%. (...) Amitriptyline is recommended as a first-line drug for prophylaxis. (This is an off-label use of amitriptyline)." assertion.
- context label "adults" assertion.
- HP_0012228 label "Tension-type headache" assertion.
- context label "adults" assertion.
- association label "Off-label ketamine treatment has shown acute antidepressant effects that offer hope for patients with therapy-resistant depression. However, its potential for integration into treatment algorithms is controversial, not least because the evidence base for maintenance treatment with repeated ketamine administration is currently weak. Ketamine is also a drug of misuse, which has raised concerns regarding the target population." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "Two other sedating antidepressants, mirtazapine and trimipramine, are commonly used off-label for the treatment of ID without clear recommendations by any of the guidelines." assertion.
- context label "adults" assertion.
- association label "This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults.(...) Several off-label drugs, especially lisinopril, candesartan, and amitriptyline also have good evidence of benefit." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- context label "adults" assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- association label ""edex (r) in men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia [see WARNINGS for the treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as cavernosal fibrosis or Peyronie's disease [see PRECAUTIONS in men with penile implants"" assertion.
- association label ""GVOKE is contraindicated in patients with: Pheochromocytoma [ see Warnings and Precautions ( 5.1 Insulinoma [ see Warnings and Precautions ( 5.2 Known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [ see Warnings and Precautions ( 5.3 Pheochromocytoma ( 4 Insulinoma ( 4 Known hypersensitivity to glucagon or to any of the excipients ( 4"" assertion.
- association label ""The use of nortriptyline hydrochloride or other tricyclic antidepressants concurrently with a monoamine oxidase (MAO) inhibitor is contraindicated. Hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. It is advisable to have discontinued the MAO inhibitor for at least two weeks before treatment with nortriptyline hydrochloride is started. Patients hypersensitive to nortriptyline hydrochloride should not be given the drug. Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."" assertion.
- association label "Furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide." assertion.
- association label ""Danazol capsules should not be administered to patients with: Undiagnosed abnormal genital bleeding. Markedly impaired hepatic, renal, or cardiac function. Pregnancy (see ). WARNINGS Breast feeding. Porphyria - danazol can induce ALA synthetase activity and hence porphyrin metabolism. Androgen-dependent tumor. Active thrombosis or thromboembolic disease and history of such events. Hypersensitivity to danazol."" assertion.
- association label "Quinapril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor." assertion.
- association label ""Oxybutynin chloride is contraindicated in patients with untreated angle closure glaucoma and in patients with untreated narrow anterior chamber angles since anticholinergic drugs may aggravate these conditions. It is also contraindicated in partial or complete obstruction of the gastrointestinal tract, paralytic ileus, intestinal atony of the elderly or debilitated patient, megacolon, toxic megacolon complicating ulcerative colitis, severe colitis, and myasthenia gravis. It is contraindicated in patients with obstructive uropathy and in patients with unstable cardiovascular status in acute hemorrhage. Oxybutynin chloride is contraindicated in patients who have demonstrated hypersensitivity to the product."" assertion.
- association label ""Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. It is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. Long-term administration of acetazolamide is contraindicated in patients with chronic non- congestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure."" assertion.
- association label ""KETEK is contraindicated in patients with myasthenia gravis. KETEK is contraindicated in patients with previous history of hepatitis and/or jaundice associated with the use of KETEK tablets, or any macrolide antibiotic. KETEK is contraindicated in patients with a history of hypersensitivity to telithromycin and/or any components of KETEK tablets, or any macrolide antibiotic. Concomitant administration of KETEK with cisapride or pimozide is contraindicated. (See CLINICAL PHARMACOLOGY, Drug-drug Interactions PRECAUTIONS Concomitant administration of KETEK and colchicine is contraindicated in patients with renal or hepatic impairment. (See WARNINGS, Drug Interactions PRECAUTIONS, Drug interactions"" assertion.
- association label ""ELLENCE is contraindicated in patients with: Severe myocardial insufficiency [see Warnings and Precautions (5.1) Recent myocardial infarction or severe arrhythmias, or previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5.1) Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4) Severe hepatic impairment (defined as Child-Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5) Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones [see Adverse Reactions (6.1) Severe myocardial insufficiency ( 4 Recent myocardial infarction ( 4 Severe persistent drug-induced myelosuppression ( 4 Severe hepatic impairment ( 4 Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones ( 4"" assertion.
- association label ""Trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Do not co-administer aliskiren with trandolapril in patients with diabetes (see PRECAUTIONS, Drug Interactions Trandolapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer trandolapril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS"" assertion.
- association label ""All diuretics, including ethacrynic acid, are contraindicated in anuria. If increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. In a few patients this diuretic has produced severe, watery diarrhea. If this occurs, it should be discontinued and not used again. Until further experience in infants is accumulated, therapy with oral and parenteral ethacrynic acid is contraindicated. Hypersensitivity to any component of this product."" assertion.
- association label ""The use of Zileuton Extended-Release Tablets is contraindicated in patients with: Active liver disease or persistent hepatic function enzyme elevations greater than or equal to 3 times the upper limit of normal (>=3xULN) [see Warnings and Precautions (5) Use in Specific Populations (8.7) A history of allergic reaction to zileuton or any of the ingredients of Zileuton Extended Release Tablets (e.g., rash, eosinophilia, etc.). Active liver disease or persistent hepatic function enzyme elevations >=3 times the upper limit of normal. ( 4 5.1 History of allergic reaction to Zileuton or any of the ingredients of Zileuton Extended-Release Tablets. ( 4"" assertion.
- association label ""Coadministration with stavudine allopurinol or ribavirin is contraindicated. ( 4 VIDEX EC is contraindicated when coadministered with the following medications: Stavudine- potential for serious and/or life-threatening events, notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [ see Warnings and Precautions 5.1 5.2 5.3 5.5 Allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [ see Clinical Pharmacology (12.3) Ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5'-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin."" assertion.
- association label ""The intravenous administration. Hypervitaminosis A. Sensitivity to any of the ingredients in this preparation. Use in Pregnancy:"" assertion.
- association label ""ORILISSA is contraindicated in women: Who are pregnant [see Use in Specific Populations ( 8.1 With known osteoporosis because of the risk of further bone loss [see Warnings and Precautions ( 5.1 With severe hepatic impairment [see Use in Specific Populations ( 8.7 12.3 With concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil) [see Drug Interactions ( 7.2 Pregnancy ( 4 Known osteoporosis ( 4 Severe hepatic impairment ( 4 Strong organic anion transporting polypeptide (OATP) 1B1 inhibitors ( 4"" assertion.
- association label ""Terbinafine tablets are contraindicated in patients with: Terbinafine tablets are contraindicated in patients with: * History of allergic reaction to oral terbinafine because of the risk of anaphylaxis * History of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see Adverse Reactions (6.2) * Chronic or active liver disease [see Warnings and Precautions (5.1) History of allergic reaction to oral terbinafine because of the risk of anaphylaxis. ( 4 Chronic or active liver disease. ( 4"" assertion.
- association label ""TEGSEDI is contraindicated in patients with: Platelet count below 100 x 10 9 [see Warnings and Precautions ( 5.1 History of acute glomerulonephritis caused by TEGSEDI [see Warnings and Precautions ( 5.2 History of a hypersensitivity reaction to TEGSEDI [see Warnings and Precautions ( 5.7 Platelet count less than 100 x 10 9 4 5.1 History of acute glomerulonephritis caused by TEGSEDI ( 4 5.2 Patients with a history of a hypersensitivity reaction to TEGSEDI ( 4 5.7"" assertion.
- association label ""VISUDYNE is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation [ see Adverse Reactions (6) VISUDYNE is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation. ( 4"" assertion.
- association label "Acute intermittent porphyria as well as allergic or idiosyncratic reactions to meprobamate or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal." assertion.
- association label ""Transderm Scop is contraindicated in the following populations: Patients with angle closure glaucoma. [ see Adverse Reactions (6)] Persons who are hypersensitive to the drug scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. [see Drug Interactions (7) Description (11) Patients with angle closure glaucoma ( 4 6.2 Persons who are hypersensitive to scopolamine or to other belladonna alkaloids ( 4 7"" assertion.
- association label ""Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug. It is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see WARNINGS"" assertion.
- association label ""Ranolazine extended-release tablets are contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions ( 7.1 Taking inducers of CYP3A [see Drug Interactions ( 7.1 With liver cirrhosis [see Use in Specific Populations (8.6 Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) ( 4 7.1 CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) ( 4 7.1 Liver cirrhosis ( 4 8.6"" assertion.
- association label ""Physostigmine Salicylate Injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). For post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine."" assertion.
- association label ""Mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. Mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes."" assertion.
- association label "Edetate calcium disodium should not be given during periods of anuria, nor to patients with active renal disease or hepatitis." assertion.
- association label "Miotics are contraindicated where constriction is undesirable; such as acute iritis, and in those subjects showing hypersensitivity to any component of this preparation." assertion.